Healthcare Industry News: Elekta
News Release - August 10, 2007
Elekta to Deliver Leksell Gamma Knife(R) to St. Petersburg, RussiaSTOCKHOLM, Sweden--(HSMN NewsFeed)--Regulatory News: Elekta (STO:EKTAB) today announced an order to deliver a Leksell Gamma Knife® 4C, to a new hospital under construction in St. Petersburg, Russia, that will become the second hospital in Russia to offer non-invasive radiosurgery for tumors and other brain disorders.
Elekta today announced an order to deliver a Leksell Gamma Knife® 4C, to a new hospital under construction in St. Petersburg, Russia, that will become the second hospital in Russia to offer non-invasive radiosurgery for tumors and other brain disorders.
The Diagnostic and Treatment Center at the International Institute of Biological Systems in St. Petersburg, Russia, will open up for patients in the spring of 2008 as privately owned center of excellence for the treatment of neurological disorders.
Following the installation of Leksell Gamma Knife, physicians at the center will be able to offer state-of-the-art technology for non-invasive brain surgery to patients in Russia and from neighboring countries.
"There are large groups of patients in Russia with brain tumors, arteriovenous malformations and other brain disorders that will benefit from our purchase of Leksell Gamma Knife, patients that otherwise had to rely on more unproven and less precise technologies for radiosurgery", comments Dr. Arkadi Stolpner, President of the Diagnostic and Treatment Center at the International Institute of Biological Systems. "With this installation we will take a huge step in increasing the treatment capacity in Russia. Stereotactic radiosurgery with Leksell Gamma Knife is an efficient and well-proven method and there is a great need for this unique technology", continues Dr. Stolpner.
Pioneered by Elekta, stereotactic radiosurgery involves delivering a single, high dose of radiation to a small and critically located target in the brain. Gamma Knife surgery has replaced the scalpel in intracranial neurosurgery. And, by doing so, it has dramatically widened treatment possibilities for physicians and patients.
Gamma Knife surgery provides pinpoint accuracy, unmatched efficiency and outstanding results. Patients benefit from fast, painless treatment, often conducted in an outpatient surgical setting without the need for general anesthesia or even convalescence. To date, about 500,000 patients have undergone Gamma Knife surgery.
Today, Gamma Knife surgery is performed in hundreds of leading hospitals and clinics around the world. Around 50,000 patients undergo Gamma Knife surgery every year, and this unique procedure has an impressive scientific track record with more than 70,000 patients documented in peer-reviewed articles. No other method in this field has gained greater clinical acceptance.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.